Argentiere Capital’s Eli Lilly LLY Stock Holding History

Argentiere Capital’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-45,000	Closed	-$5.84M	–	14
2019 Q1	$5.84M	Sell	45,000 -5,000	-10%	-$608K	2.54%	12
2018 Q4	$5.79M	Buy	+50,000	New	+$5.59M	1.81%	5
2016 Q1	–	Sell	-250,000	Closed	-$244K	–	79
2015 Q4	$244K	Buy	+250,000	New	+$20.7M	0.11%	48

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Argentiere Capital's LLY Position: Q2 2018 in Review

Argentiere Capital sold out of Eli Lilly (LLY) in Q2 2018, closing a stake of 31,465 shares — an estimated $2.43M sold.

Argentiere Capital first reported a position in LLY in Q4 2015 and held it in 4 quarters. The position peaked at $2.43M in Q1 2018. 1,369 funds tracked by Wall St. Rank hold LLY as of Q2 2018.

Argentiere Capital reported no remaining Eli Lilly position as of Q2 2018 after selling out during the quarter.
Argentiere Capital sold 31,465 Eli Lilly shares in Q2 2018, an estimated $2.43M.
Argentiere Capital first reported a position in Eli Lilly in Q4 2015 and held it in 4 quarters.
Argentiere Capital's Eli Lilly position peaked at $2.43M in Q1 2018.
1,369 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2018.

Based on Argentiere Capital's 13F filing for Q2 2018, filed 14 Aug 2018.